Specific lactagogues--drugs which stimulate the secretion of

milk--are unknown to science. Yet medical publications give space

to advertisements of a proprietary--“Nutrolactis”--which is said to

increase the milk supply of nursing mothers. Since dependence on

a preparation of this kind is likely to cause neglect of the only

means of increasing a scanty milk supply of nursing mothers--care of

the general health and a sufficient quantity of proper food--this

proprietary and the drug “goat’s rue,” (_Galega officinalis_) which the

proprietors hint as being the potent constituent, were subjected to a

critical study to determine their possible influence on milk secretion.

For this purpose the Council secured the help of A. J. Carlson, Ph.D.,

professor of physiology, University of Chicago. Dr. Carlson, with

the aid of A. Woelfel, M.D., and Marian Lewis, Sc.M., undertook to

estimate the effect of Nutrolactis and of goat’s rue on nursing dogs

and goats with the intention of extending the study to nursing mothers

if the animal experiments so warranted. The contribution, “The Alleged

Galactagogue Action of Galega and Nutrolactis,” by Marian Lewis and

A. J. Carlson from the Hull Physiological Laboratory of the University

of Chicago, which appears below, shows that Nutrolactis and goat’s rue

are without influence on the milk secretion in nursing animals.

The Council endorsed the work of Lewis and Carlson and held that the

claimed galactagogue effects of Nutrolactis and goat’s rue are not

substantiated.

W. A. Puckner, Secretary.

THE ALLEGED GALACTAGOGUE ACTION OF GALEGA AND NUTROLACTIS[D]

Marian Lewis, Sc.M., and A. J. Carlson, Ph.D.

CHICAGO

[D] From the Hull Physiological Laboratory of the University of Chicago.

[D] This investigation was begun in 1915 by Drs. A. Woelfel and A. J.

Carlson.

It is well established that the food best adapted to the energy and

growth requirements of the infant is normal mother’s milk. Any decrease

in quantity or deterioration in quality of the maternal secretion is

soon followed by a parallel impairment of growth, loss of weight,

or lowered resistance to infection in the infant. The widespread

occurrence of deficient milk secretion is a matter of common knowledge.

The discovery of true lactagogues, or specific substances which

increase the quantity and quality of the milk on being administered to

nursing mothers, would therefore be of very great importance. In view

of this great medical and economic interest in true lactagogues it is

not surprising to find that the medical and biologic literature records

discoveries of lactagogues based on hope rather than demonstration, and

that spurious lactagogues are on the market.

Some of the factors known to affect milk secretion are general health,

food supply, psychic state, and heredity. The mechanism of secretion

and the method by which these factors affect it are imperfectly

understood. In general it has been observed that milk yield improves

both in quantity and in quality with improvement in general health,

better food supply, and more favorable psychic state. The influence of

heredity is taken advantage of by dairymen who are well acquainted with

the potential milk production of the different breeds of cattle.

Among the substances which have been reported to stimulate milk

secretion may be mentioned the extract of the posterior lobe of the

hypophysis. But pituitary extract is not a true lactagogue, because

its action is confined to the smooth musculature of the gland ducts,

causing a more or less complete ejection of the milk already formed;

it has no effect on the gland cells or the actual secretory process in

the direction of increasing the milk yield. Extracts of thymus, corpus

luteum, ovaries, uterus, placenta, fetus, and the mammary gland itself

have also been reported to have a temporary stimulating effect on the

quantity of milk secreted, but when these extracts are given by mouth

they are apparently without specific influence on the mammary gland.

Galega, or goat’s rue (_Galega officinalis_), is an herb described in

the National Formulary as being slightly bitter and astringent. In

1873, Gillet-Damotti,[112] in a communication to the French Academy,

stated that this plant when fed to cows increases the secretion of

milk from 35 to 50 per cent. Other French writers have affirmed that

goat’s rue is a lactagogue. In Germany, Fragner[113] made a preparation

called Galegal, using galega as the active principle and combining it

with lactose to give it a pleasant taste and make it soluble in water,

milk, coffee, and tea. This preparation was reported on favorably

by Scherer,[114] who asserts that he obtained positive results in

fifty-four of the eighty cases in which he used it.

[112] Gillet-Damotti: Comp. rend. Acad. d. Sc., July 7, 1873.

[113] Fragner: Wien. med. Wchnschr. =60=:1033-1036, 1910.

[114] Scherer: Wien. med. Wchnschr. =60=:1033-1036, 1910.

More recently Huët[115] tested the effects of Theinhardt’s Hygiama

lactogene on four lactating women. This preparation is said to be

composed of hygiama,[116] galega and anise. Analysis showed that it

contains albumins, fat, soluble and insoluble carbohydrates, salts

and water. Huët could not observe any influence from the use of this

preparation, either on the quantity or on the composition of the milk

secreted.

[115] Huët: Nederlandsch Tijdschr. v. Geneesk. =1=:1353-1370, 1914.

[116] Hygiama is said to be a food consisting of condensed milk, with

(fatless) cocoa and cereals added to it (Encyclopedia and Dictionary of

Medicine and Surgery, 1907).

Nutrolactis[117] is a commercial preparation sold by the Nutrolactis

Company of New York at $1 a bottle. The label states that it contains

5 per cent. of alcohol; that it contains fluid extracts of the family

of “galactagogic plants,” and that it is intended to “increase the

supply of mother’s milk.” It is recommended to maintain “quality and

quantity until the end of normal lactation.” Nutrolactis is also

recommended for a mother debilitated by lactation. It is claimed that

“Nutrolactis does not _force_ the secretion of milk but merely assists

such secretion.” Years ago Millbank[118] reported good results from the

use of Nutrolactis. After more than a year’s use he concluded that it

was more satisfactory than any other lactagogue hitherto employed by

him, which is not saying very much, as specific lactagogues are as yet

unknown. Nutrolactis is still (1916) extensively advertised in various

medical journals as a lactagogue.

[117] The North Dakota Agricultural Experiment Station has recently

published (Bulletin 22, 1915, p. 386) a complete chemical analysis

of Nutrolactis. It contains only 0.60 per cent. solids (including

strychnin and emodin). It has a bitter taste. The alcohol content was

3.5 per cent. The report concludes: “a little strychnin, a little

alcohol, and a little laxative is about all there is to cause an

increase in the milk secretion.”

[118] Millbank: New York M. J. =50=:544, 1889.

METHODS OF INVESTIGATION

The alleged lactagogue action of galega and Nutrolactis was tested

on lactating dogs and goats. In these animals the psychic factors,

or suggestion, are largely eliminated. If the results had been

positive or had indicated lactagogue action, the test would have been

extended to nursing women. The puppies and kids were weighed before

and after nursing and a record kept of the amount of milk obtained at

each nursing (the animals nursing from three to five times daily).

The mothers were fed with varying doses of the drugs, and the milk

yield compared with that of a control period during which no drugs

were administered. An effort was made to keep the conditions of the

experiments uniform throughout.

The galega was ground and mixed with the food. The Nutrolactis was

mixed with food given by the stomach tube, or in some cases with a

spoon. Galega was tested on two goats and Nutrolactis on one goat and

nine dogs. The results are given herewith:

GALEGA

_Goat 1_: Control period, 1,600 gm., milk av. daily yield for 7 days.

Galega period (30 gm. galega mixed with oats), 860 gm., milk av.

daily yield for 8 days. Kids weaned at end of period.

_Goat 2_: Control period, 1,161 gm. milk av. daily yield for 9 days.

Galega period (30 gm. galega mixed with oats), 860 gm. milk av. daily

yield for 8 days. (25 gm. galega in same way), 810 gm. milk av. daily

yield for 10 days.

Control period, 896 gm. milk av. daily yield for 6 days.

NUTROLACTIS

_Goat 3_: Control period, 896 gm. milk av. daily yield for 6 days.

Nutrolactis period (30 c.c. Nutrolactis mixed with oats), 658 gm.

milk av. daily yield for 9 days.

Control period, 666 gm. milk av. daily yield for 5 days.

_Dog 1_: Control period, 176 gm. milk av. daily yield for 7 days.

Nutrolactis period (8 c.c. Nutrolactis by stomach tube), 55 gm. milk

av. daily yield for 12 days.

_Dog 2_: Control period, 189 gm. milk av. daily yield for 6 days.

Nutrolactis period (8 c.c. Nutrolactis by stomach tube), 72 gm. milk

av. daily yield for 11 days.

_Dog 3_: Control period, 93 gm. milk av. daily yield for 8 days.

Nutrolactis period (8 c.c. Nutrolactis on bread), 17 gm. milk av.

daily yield for 5 days.

_Dog 4_: Control period, 28 gm. milk av. daily yield for 7 days.

Nutrolactis period (8 c.c. Nutrolactis by stomach tube), 47 gm. milk

av. daily yield for 6 days.

(10 c.c. Nutrolactis by stomach tube), 43 gm. milk av. daily yield

for 8 days.

Control period, 41.5 gm. milk av. daily yield for 6 days.

Nutrolactis period (10 c.c. Nutrolactis by stomach tube), 33.5 gm.

milk av. daily yield for 4 days.

_Dog 5_: Control period, 67 gm. milk av. daily yield for 6 days.

Nutrolactis period (10 c.c. Nutrolactis on bread), 81 gm. milk av.

daily yield for 6 days.

_Dog 6_: Control period, 40 gm. milk av. daily yield for 5 days.

Nutrolactis period (10 c.c. Nutrolactis by stomach tube), 33 gm. milk

av. daily yield for 8 days.

Control period, 26 gm. milk av. daily yield for 4 days.

_Dog 7_: Control period, 283 gm. milk av. daily yield for 9 days.

Nutrolactis period (10 c.c. Nutrolactis by stomach tube), 155 gm.

milk av. daily yield for 15 days.

(15 c.c. Nutrolactis by stomach tube), 82 gm. milk av. daily yield

for 6 days.

Control period, 33 gm. milk av. daily yield for 3 days.

_Dog 8_: Control period, 238 gm. milk av. daily yield for 8 days.

Nutrolactis period (20 c.c. Nutrolactis on bread), 223 gm. milk av.

daily yield for 4 days.

(20 c.c. Nutrolactis on bread), 46 gm. milk av. daily yield for 6

days.

_Dog 9_: Control period, 223 gm. milk av. daily yield for 6 days.

Nutrolactis period (10 c.c. Nutrolactis on bread), 178 gm. milk av.

daily yield for 15 days.

(15 c.c. Nutrolactis on bread), 146 gm. milk av. daily yield for 5

days.

COMMENT AND CONCLUSION

Goat 1 had already been lactating for over two months, and the yield

was gradually decreasing at the time the observations were begun. The

administration of galega did not check this decrease. Goat 2 should

have been a very favorable subject, for the kid was about a week old

at the time the observations were begun. Both galega and Nutrolactis

caused a decrease in milk yield of this animal. This decrease is

perhaps partly due to the animal’s distaste for the drugs and her

consequent failure to eat as well as during the control periods.

Administration of Nutrolactis was accompanied by an increase in milk

in only two animals, Dog 4 and Dog 5. A detailed examination of the

records of these two dogs shows that in both cases _there was a

progressive increase in milk yield during the control period_ and that

administration of the drug failed to accelerate this increase. On the

contrary, the curve for Dog 5 takes a sudden drop immediately after the

first administration of the drug.

The records of Dogs 6 and 7 show that the yield during the second

control period is lower than that of the preceding periods. Although

the administration of the drug in both cases was followed by a decrease

in the yield, it may be urged that the drug has some lactagogue action,

for its discontinuance was followed by a decrease in yield. This

effect, however, is also apparent rather than real, for the data show a

gradual falling off in yield during the period of administration of the

drug, which decrease was not accelerated by withdrawing the drug.

Our data show that galega and Nutrolactis, when taken by mouth,

and the elements of suggestion excluded, had no beneficial effect

on lactation--at least in so far as the quantity of milk is

concerned.--(_From The Journal A. M. A., May 26, 1917._)

THE RUSSELL EMULSION AND THE RUSSELL PREPARED GREEN BONE

Report of the Council on Pharmacy and Chemistry

The following report on “The Russell Emulsion” and “The Russell

Prepared Green Bone,” marketed by the Standard Emulsion Company, was

submitted to the Council by a referee. The Council endorsed the report

and authorized its publication.

W. A. Puckner, Secretary.

The Russell Emulsion is put up in a neat package and advertised in an

attractive pamphlet, on the cover of which we are told: “Truth Always

Justifies The Superlative Degree.” As what follows in the booklet and

in the printed circulars certainly does not lack superlatives, this is

doubtless a warning.

In addition to the pamphlet and circular advertising, the product seems

to be systematically boomed by a lecture scheme in which one Dr. Hague

talks before medical societies and distributes advertising matter.

The lecture is succeeded by a follow-up letter scheme through which

matter is sent to members of the society. Hague ostensibly discusses

“lime starvation in tuberculosis,” but medical societies soon learned

to estimate his work as essentially to advertise the Russell products.

Last April the Medical Society of the State of Pennsylvania sent out

a circular letter to its county organizations on the subject of the

Russell-Hague propaganda which opens in this way:

“You have doubtless received a letter from Dr. William Grant Hague of

New York, offering to address your county society on Tuberculosis.

After due investigation, it is respectfully suggested that it may not

be desirable to ask him to address your society....”

The statements in the pamphlet and circular published are typical of

the whole method of exploitation. For example, can such claims as these

be surpassed by the veriest quack?

“SCIENCE cannot improve the means employed in producing THE RUSSELL

EMULSION.”

“GENIUS has not devised better methods than are used in

manufacturing THE RUSSELL EMULSION.”

“MONEY cannot buy better products than are used in THE RUSSELL

EMULSION.”

“EXPERIENCE cannot suggest a more nutritious combination of fats

than we use in THE RUSSELL EMULSION.”

The emulsion is said to be made of equal parts of beef-fat, coconut,

peanut and cottonseed oils, held in suspension by albumin. The latter

we are told is applied to each globule of the emulsion by an “elaborate

technical process” devised by Dr. Russell. The mixture is everywhere

spoken of as a “physiological” emulsion, but the word is always in

quotation marks. Why it is called “physiological” is not clear, but the

term may be counted on to impress the unthinking or the unscientific.

Numerous false and exaggerated statements are made about this

“physiological” emulsion with reference to food value. For instance:

“The nutritional value of fats differ; the nutritional value of

these fats and their increased efficiency by combination over all

others have been determined by extensive clinical observation.”

And also:

“The Russell Emulsion is approximated in food value by no other

emulsion or food product in existence.”

“A ‘physiological’ emulsion is a predigested food. It is absorbed

with little assistance from the digestive juices, and with no waste

of energy. It is, therefore, the ideal food....”

These are sample statements found in the pamphlet and accompanying

circular. A dozen or more pathologic conditions are mentioned in which

this “ideal food” is specifically indicated; but we find, also, this

curious statement: “Patients can rarely take this dose [speaking of the

maximum dose of 2 ounces night and morning] for more than three or four

weeks without showing symptoms of over-feeding.” This unguarded remark

about an ingestion of 48 grams of fat daily prompts one to ask what is

wrong with the “ideal predigested food.”

Russell is wedded to the idea that “lime starvation” is the main factor

in tuberculosis, and insists on the importance of large amounts of fat

for the “lime starved.”

“Dr. Russell was the original interpreter of the Lime Starved State

and originated The Lime Starvation Treatment in Tuberculosis. He

also first pointed out and emphasized the therapeutic importance of

regarding the combination of lime phosphate and casein, as brought

down by the rennet enzyme, as a chemical union.”

This overworked lime-starvation theory certainly lacks any tangible

confirmation (see in this connection a recent paper by Halverson,

Mohler and Bergeim, in The Journal, May 5, 1917), and to urge it

to promote the sale of a fat preparation is preposterous. On the

uninitiated the exaggerated pseudo-scientific language of the pamphlet

and circular advertisement will probably make some impression.

Unfortunately such things count not only with the layman who, having

no technical knowledge of physiology, cannot be expected to weigh the

evidence but also with those medical men who, while scientifically

educated, are influenced by unscientific claims when plausibly

presented. The pamphlet is a striking example of a style which is

dangerous because it smacks of science.

The Russell Company sells also a mixture called “Prepared Green Bone,”

said to be made by partially digesting ground chicken bones with

hydrochloric acid and pepsin and adding glycerin at the end of the

digestion. The product is a sticky, unappetizing looking mass, put up

in little earthenware boxes and advertised as a lime food, apparently

to go along with the fat emulsion. The greater value of a few glasses

of milk daily is evidently overlooked.

“The Russell Emulsion” and “The Prepared Green Bone” were declared

inadmissible to New and Nonofficial Remedies.

[Editorial Comment.--There are always those who are ready to exploit

the unfortunate tuberculous. It is, unfortunately, a fact that many

physicians accept as true, statements clothed with obscure and

voluminous quasi-scientific verbiage. Such men would laugh at the

bald claim that the moon is made of green cheese; when, however, one

plausibly and with due solemnity, affirms that the nocturnal luminous

earthly satellite is composed of an infinite aggregation of molecules

of bewildering and awe-compelling complexity, built up from the

recently discovered polypeptids, the whole being of a verdant tint, the

person addressed looks impressed and opines that it sounds reasonable!

The advertising for The Russell Emulsion and The Russell Prepared Green

Bone is dangerous because it appeals to the thoughtless--layman and

physician, alike.]--(_From The Journal A. M. A., June 23, 1917._)

BROM-I-PHOS

Report of the Council on Pharmacy and Chemistry

Brom-I-Phos (National Drug Company, Philadelphia) was submitted to the

Council with a label bearing the following statement:

“‘ALCOHOL 25 PER CENT.’

COMPOSITION--Per Fluidounce

Iodin 1 gr.

Bromin 1 gr.

Phosphorus 8-100 gr.

Aromatic Base q. s.”

A request for further information in regard to the composition of

Brom-I-Phos was sent to the National Drug Company. It was suggested

that since the preparation cannot contain the stated amounts of free

bromin, free iodin and free phosphorus, the form of combination in

which these elements are present should be set forth. In reply,

the firm said, first, that “Brom-I-Phos consists of Bromin, Iodin,

Phosphorus, Glycerin, Wine, Water and Volatile Oils. The Iodin is

rubbed up with a small percentage of Potassium Iodid and 95 per cent.

Alcohol, which solution is mixed with a solution of Bromine and

Spirits of Phosphorus which are combined with the base and aromatics.”

The manufacturer also admitted that phosphorus reacts with bromin

and iodin and that other reactions might occur, but maintained that

it was “justified in assuming the greater part, if not all of these

elements, are actually existent in the nascent state,” and asserted

that its “printed formula complies with our working formula in point of

quantities involved as well as existence of elements in an uncombined

state.”

The A. M. A. Chemical Laboratory reported, on the contrary, that

no free phosphorus, free bromin or free iodin could be found in

Brom-I-Phos, and that no bromate or iodate could be found; bromid and

iodid were present. The addition of silver nitrate to an acidulated

portion, diluted with water, gave an amount of silver halid roughly

agreeing with that which would be obtained had the claimed amount of

bromin and iodin (together with some potassium iodid) been used in the

preparation of Brom-I-Phos and in the process of manufacture become

converted to bromid and iodid.

The Council declared Brom-I-Phos inadmissible to New and Nonofficial

Remedies, for conflict with Rules 1, 4, 6, 8 and 10.

The statement of composition is unsatisfactory and misleading in that

it suggests that the preparation contains bromin, iodin and phosphorus

in the free (elementary) state. The presence of the potent elementary

phosphorus is especially suggested by the small amounts of “phosphorus”

declared.

The following statement on the label of the trade package constitutes

an indirect advertisement to the public:

“INDICATIONS: Scrofula, Coryza, Hay Fever Necrosis, Bronchial and

Throat Affections, Catarrhal Pneumonia, Glandular enlargements of

the Spleen, Thyroid, and Lymphatics, Rickets and Syphilis.”

The following claims are therapeutic exaggerations:

“The Ideal Alterative”

“... indicated in all cases where an alterative is desired ...”

“The association of Bromin with Iodin in Brom-I-Phos materially

enhances the product in the treatment of chronic affections of

the skin, depraved conditions of the mucous membranes, tertiary

syphilis, glandular enlargements, etc.”

In that it suggests that the phosphorus in Brom-I-Phos is more readily

assimilated than ordinary phosphate, the following is misleading:

“The Phosphorus contained in Brom-I-Phos is readily assimilated and

at once acts as a nutrient to the nervous and osseous structures of

the body, stimulates metabolism and increases mental activity.”

The recommendation: “Your specification of Brom-I-Phos in the

treatment of Syphilitic cases will immediately prove beneficial to the

patient” is not supported by evidence. The name does not indicate that

Brom-I-Phos is an alcoholic preparation with iodid as its essential

constituent, but suggests that phosphorus is an important constituent,

whereas the amount of phosphate or phosphite, produced by the action

of iodin on elementary phosphorus (if the amount of phosphorus used in

making the preparation is correctly stated) is insignificant.

The combination of bromin, iodin and phosphorus, or bromid, iodid and

phosphate, is irrational because these elements are not of mutual

assistance to each other in the conditions for which Brom-I-Phos is

advertised.

The Council’s report was submitted to the manufacturer of Brom-I-Phos

for comment; the reply contained nothing to permit a revision of the

previous conclusions.

The Council declared Brom-I-Phos inadmissible to New and Nonofficial

Remedies.--(_From The Journal A. M. A., June 30, 1917._)

CREOSOTE-DELSON AND CREOFOS

Report of the Council on Pharmacy and Chemistry

Creosote-Delson and Creofos, or Creosote with Hypophosphites,

were submitted by the Delson Chemical Co., Inc., New York City.

Creosote-Delson is said to be “beechwood creosote from which

the irritating and caustic properties are removed by fractional

distillation.” It is claimed that Creofos contains “2 grains of

Creosote-Delson and 3-3/5 grains of the combined Hypophosphites in each

fluidrachm of the mixture or emulsion, the lime salt predominating.”

It is also claimed that “the primary object of the hypophosphites in

this preparation is that of maintaining the refined creosote in a

pure, unoxidized state, and that no particular claim for therapeutic

action on their part is advanced.” It is explained further, however,

“the addition of the lime was prompted by the belief ... that the

fundamental cause of pulmonary tuberculosis is lime starvation....”

The assertions are made that Creosote-Delson is superior to the

official creosote because it can be taken “abundantly and persistently

without harm to or interference with stomach and kidneys” and can

be “taken uninterruptedly and indefinitely,” while the dosage

is “unlimited by any former knowledge of Creosote Therapy.”

Creosote-Delson is not on the market except in the combination Creofos,

although it is supplied on request.

Creofos is advised in the treatment of tuberculosis, whooping cough,

measles, “Grippe and Colds,” bronchitis, asthma, “Intestinal Affections

(Colitis, Summer Diarrhoea, etc.),” while its use is suggested for the

“prevention of the spread of contagious diseases,” and for “preventing

contagion in minor contagious diseases at any rate, in schools and

families.”

The following advertisement has recently appeared in the _New York

Medical Journal_ and in the _Therapeutic Gazette_:

CREOFOS MEDICATION

is the successful development of the most advanced practice in

the treatment of infectious diseases. It destroys completely the

causative organisms by a bactericide many times more powerful than

phenol, yet absolutely harmless to animal life.

Unlike serums, its activity is not confined to any specific

disease, and its use insures against sequelae (as pneumonia

following grippe).

Especially valuable in the treatment of infants and patients of

delicate constitution and in cases where time is of importance.

The Delson Chemical Co. was requested to supply information regarding

the identity of Creosote-Delson and to support the claim that although

it is “the whole drug” its dosage is “unlimited by any former knowledge

of Creosote Therapy.” The reply was virtually an admission that the

toxic, caustic, phenolic components of creosote were present in

Creosote-Delson just as in the official creosote.

The referee of the Committee on Therapeutics in submitting his report

to the Council pointed out that it is difficult to discuss the

pharmacologic merits of a semisecret preparation, like Creosote-Delson,

claimed to be more acceptable to the human organism than the official

product it is intended to supplant, when the action of the parent drug

is still questioned or disputed by eminent clinicians.

Absorption experiments have been carried out with creosote and creosote

compounds, such as creosote with hypophosphites or calcium or creosote

carbonate, chiefly by a study of the elimination products in the urine.

But any evidence so far offered that these combinations increase

absorption and lessen the irritating, caustic or toxic properties has

been wholly inconclusive. The evidence offered by the Delson Chemical

Co. presented no control experiments with the official creosote and did

not prove that either Creosote-Delson or Creofos was less toxic than a

corresponding amount of ordinary beechwood creosote.

The referee concluded that no proof had been offered that these

preparations are materially superior to ordinary creosote preparations

from the pharmacologic or therapeutic standpoint, and that the claims

made for Creosote-Delson and Creofos are unwarranted in the light of

our knowledge of the properties of creosote. The advertisement quoted

above is an example of unproved and unwarranted claims.

On the recommendation of the referee, the Council declared

Creosote-Delson and Creofos inadmissible to New and Nonofficial

Remedies, for conflict with the rules as follows:

_Creosote-Delson_: The information so far available is not sufficient

to define the nature, or composition, of Creosote-Delson, or to

indicate in how far this product differs, if at all, from the

official creosote (conflict with Rule 1). No methods are furnished

for determining the identity or composition of Creosote-Delson

(conflict with Rule 2). The available information does not show that

Creosote-Delson has advantages over creosote (conflict with Rule 6).

_Creofos_: The composition of Creosote-Delson not having been

furnished, the statement concerning the composition of Creofos is

also unsatisfactory (conflict with Rule 1). The therapeutic claims

are unsubstantiated and grossly exaggerated (conflict with Rule 6).

The name is not descriptive of its composition as is required for

pharmaceutical mixtures (conflict with Rule 8). There is no evidence

that hypophosphites prevent decomposition of creosote (if this

occurs). Hence the inclusion of hypophosphites must be considered

irrational (conflict with Rule 10).

The Council’s report was sent to the Delson Chemical Co. for

consideration. The firm’s reply contained nothing to warrant a revision

of the report, and the Council voted that Creosote-Delson and Creofos

were inadmissible to New and Nonofficial Remedies and authorized the

publication of this report.--(_From The Journal A. M. A., July 7,

1917._)

TRINER’S AMERICAN ELIXIR OF BITTER WINE

Report of the Council on Pharmacy and Chemistry

Triner’s American Elixir of Bitter Wine is a wine to which bitter drugs

and laxatives have been added. Though evidently intended for public

consumption, it is also advertised to physicians, and consequently the

Council publishes this report.

Some recent advertisements read:

“It Acts Well and Is Very Palatable. These are the reasons why so

many physicians recommend TRINER’S AMERICAN ELIXIR OF BITTER WINE.

Free from any chemicals. Prepared from bitter herbs roots and barks

of eminent medicinal value and pure natural red wine. A safe relief

in auto-intoxication, constipation, weakness, etc. Price $1.00. At

drug Stores. Samples gratis upon request only to physicians.”

“A Laxative Tonic. In cases of constipation and its sequelæ,

autointoxication, weakness and nervousness you should try _Triner’s

American Elixir of Bitter Wine_. This preparation consists of

Cascara Sagrada, Dandelion, Gentian Root, with Licorice in Pure Red

Wine as a base, with Aromatics.”

Triner’s American Elixir of Bitter Wine is put up in bottles said to

hold 1 pint, 5-1/3 fluidounces. The label declares the presence of from

16 to 18 per cent. alcohol by volume, and states that “no special tax

is required by the laws of the U. S. for the sale of this medicinal

preparation.” The circular contains the following recommendations for

its use:

“... It should be used in all cases calling for a safe evacuation

of the bowels, without weakening the body or causing any pain or

other discomfort; in loss of appetite, nervousness and weakness.”

“Triner’s American Elixir of Bitter Wine consists of two principal

ingredients, viz., Red Wine and Medicinal Herbs.”

“Red Wine strengthens the intestines and regulates their work. It

also increases the appetite, stimulates and strengthens the body.”

“Use Triner’s American Elixir of Bitter Wine always when a thorough

cleaning out of the intestines is needed. Arrange the dose to suit

your condition and habits.”

“In Chronic Constipation the dose of Triner’s American Elixir of

Bitter Wine should be increased or taken oftener.”

“Many Female Troubles are caused or aggravated by constipation and

ladies should always pay good attention to this fact.”

In addition to Triner’s Elixir of Bitter Wine, the circular--in

English, Polish, Russian, Spanish and other languages--advises the

use of Triner’s Angelica Bitter Tonic, Triner’s Red Pills, Triner’s

Liniment and Triner’s Cough Sedative.

The composition of this “wine”--some bitter drugs, a laxative and a

tannin-containing, constipating red wine--and advertising propaganda

all tend to the continued use of this alcoholic stimulant and thus to

the unconscious formation of a desire for alcoholic stimulation. As

the medical journal advertisements may lead physicians to prescribe

this secret and irrational preparation and thus unconsciously lead to

alcoholism, the Council authorized publication of this report.--(_From

The Journal A. M. A., July 14, 1917._)

TRIMETHOL

Report of the Council on Pharmacy and Chemistry

Trimethol is the trade name for a substance said to be

trimethyl-methoxy-phenol of the formula C₆H(CH₃)₃(OCH₃).OH--1:2:4:5:6,

originated by J. T. Ainslie Walker. It is sold as a nontoxic germicide,

having a Rideal-Walker phenol-coefficient of 40, even in the intestinal

canal. It is described as insoluble in water and not to be decomposed

in the alimentary tract, and to be excreted unchanged in the feces.

Trimethol itself is not obtainable. Pharmaceutical

preparations--Trimethol Syrup, Trimethol Capsules and Trimethol

Tablets, said to contain Trimethol--are prepared by The Walker-Leeming

Laboratories and sold by Thos. Leeming and Co., New York.

Trimethol preparations are advertised for use in all conditions

dependent on intestinal putrefaction. The advertising claims made are

very extensive and some of them give to “Trimethol” the scope of a

panacea. For example:

“Physicians are constantly reporting cases where Trimethol has been

especially efficient, and describing conditions (until recently not

associated with intestinal infection) which have been distinctly

benefited by its use. This would seem to bear out the contentions

of Charcot and Metchnikoff that 90% of all human ailments have

their origin in intestinal infection.

“The careful practitioner, when in doubt, will bear this in mind,

now that we have a really efficient and non-toxic intestinal

germicide--not a mere antiseptic.”

The Walker-Leeming Laboratories have not formally requested the Council

to consider the Trimethol preparations, though in a personal letter to

a member of the Council J. T. Ainslie Walker invited an investigation

of his compound.

For the investigation of Trimethol and its preparation the Council

secured the aid of a bacteriologist who has given much attention to

the study of the intestinal flora. The Walker-Leeming Laboratories and

J. T. Ainslie Walker were both asked to submit details of experimental

studies and also to furnish a supply of the pure “Trimethol.” But the

only data sent that had any definiteness set forth the bacterial counts

made of plate cultures of stools of one patient before and after the

administration of Trimethol Capsules.

REFUSE TO FURNISH TRIMETHOL

The request for the pure substance was refused, on the grounds that the

substance was not used in the undiluted form. The failure to furnish

the chemical substance claimed as the essential constituent of the

Trimethol preparations is to be deprecated if indeed it has not greater

significance. At least it made it impossible for the Council’s expert

to express his results in terms of absolute Trimethol of established

composition. The data obtained apply only to the market preparations

claimed to contain Trimethol. So far as the investigation and report

go, “Trimethol” is a hypothetical substance.

Clinical or animal tests of the asserted intestinal antiseptics have

hitherto given equivocal results because it is impossible, on the

one hand, to predict the course of any intestinal infection, or,

on the other hand, to determine what effect, if any, was produced

by administration of the medicament. It therefore seemed unwise to

undertake this line of investigation until the more direct laboratory

bacteriologic methods had been exhausted. Consequently the investigator

checked, in the first place, the phenol coefficient of one of the

Trimethol preparations and then also determined its “penetrability”

coefficient. Although by both methods Trimethol was found to be a

germicide, the results did not indicate any remarkable potency or other

properties suggesting that the drug possessed special therapeutic

value. From the results obtained it appeared inadvisable to proceed

further with the work until more definite evidence of the nature and

of the value of the substance should be at hand. The report of the

bacteriologic investigation follows:

THE BACTERIOLOGIST’S REPORT

“I have made no attempt to study the effects of internal administration

of Trimethol on the intestinal flora. The methods available at the

present time of enumerating the numbers of _viable_ bacteria in

the feces are probably not accurate within 100 per cent. and the

precision of such determinations is equally variable. The physiologic

factors involved are so complex that they would appear to make a

really valuable assay a question of many months’ careful study. If

it were possible to administer known amounts of Trimethol, as such,

the problem might be worth while; inasmuch as the available reactive

substance is not at present quantitatively assayable, this phase of the

investigation barely seems practicable.

“‘Trimethol Syrup,’ as such, appears to be about 10 per cent. as

efficient in its germicidal value as carbolic acid. If the assay,

3/4 m. Trimethol per drm. (as the label indicates), is correct, the

substance would appear to possess germicidal merit provided enough

could be administered, if it is not influenced by passage through the

stomach.

“A package containing four four-ounce bottles labeled ‘Trimethol, A

Non-Toxic Germicide SYRUP Representing 3/4 m. Trimethol per drm.,

Alcohol 1-1/2 per cent.’ was received at the laboratory Dec. 15,

1916. Later a smaller package containing, according to the label, 100

Trimethol tablets, each 5 gr., representing 1-1/4 m. Trimethol, was

received. The tablets were apparently chocolate coated.

“Two separate series of tests were made upon the syrup. (_a_) PHENOL

COEFFICIENT, using the method outlined in _Bulletin No. 82_, Hygienic

Laboratory, Method of Standardizing Disinfectants With and Without

Organic Matter. (_b_) A PENETRABILITY COEFFICIENT by the method of

Kendall and Edwards, _Journal of Infectious Diseases_, 8, 250.

“The former method compares the viability of naked germs in a 1 per

cent. carbolic acid solution as a standard, with various dilutions

of the germicide to be tested. The latter measures the relative

diffusibility and germicidal power of carbolic acid and various

dilutions of the germicide to be tested upon _Bacillus coli_ suspended

in 1.2 per cent. agar which is molded in cylinders of one centimeter

diameter after infection with the organism.

“The first method--phenol coefficient--possesses advantages and

disadvantages which are well known and need no mention here. It is

worthy of notice, however, that as the death rate of the bacteria

increases during the progress of the test, it becomes increasingly

difficult to maintain a uniform suspension of living organisms so

that each loopful removed shall exactly represent the developmental

potentiality of the residual organisms.

“The second method theoretically covers the possibility because all the

organisms are immobilized and are exposed to the germicide in direct

proportion to its diffusibility until the center of the agar mass is

reached, where the residual viable bacteria are presumably located.

Inasmuch as the penetrability of an intestinal mass is involved in a

discussion of intestinal germicides, the propriety of utilizing this

‘penetrability coefficient’ in this connection is obvious, in spite of

its patent shortcomings.

“It is unnecessary to discuss the technique--the standard broth

mentioned in the Hygienic Bulletin, a temperature of 70 F., a standard

4 mm. loop and careful attention to dilutions (using distilled water)

were all observed. The various dilutions of Trimethol Syrup were made

with accurate volumetric pipettes, measuring flasks and distilled water

was used as a diluent.

“The results of several determinations, using Trimethol Syrup from

three separate bottles, were in sufficient accord to warrant the

statement that a dilution of 1/10 of Trimethol Syrup was equivalent

to a 1/100 dilution of carbolic acid, using _Bacillus typhosus_ as

the test organism. Both solutions--the Trimethol and phenol--killed

the organism in the interval between 7-1/2 minutes and 10 minutes’

exposure. That is to say, our observations indicate that under

standard conditions as defined above, a 10 per cent. solution of

Trimethol Syrup is equivalent in germicidal powers, as defined by the

phenol coefficient to a 1 per cent. solution of phenol. Naturally, no

predictions can be drawn from these observations indicative of the

value as an intestinal germicide of Trimethol itself.

“The PENETRABILITY COEFFICIENT resulted as follows: A 5 per cent.

solution of phenol killed _Bacillus coli_, suspended uniformly

throughout a cylinder of 1.2 per cent. agar in the interval between

60 and 90 minutes. A 1 per cent. solution of phenol killed the same

organisms under the same conditions in the interval between two and

one half and three hours. An undiluted solution of Trimethol Syrup

killed the organisms in the interval between two and one half and three

hours. A 10 per cent. solution (nine volumes of distilled water to one

volume of Trimethol Syrup) failed to kill the organisms in four hours.

It would appear that undiluted Trimethol Syrup has the same combined

penetrability and germicidal value as a 1 per cent. phenol solution.

“The PHENOL COEFFICIENT: A 10 per cent. solution of Trimethol Syrup

in distilled water (nine volumes of distilled water to one volume of

Trimethol Syrup) possesses the same germicidal power as a 1 per cent.

solution of carbolic acid. This coefficient takes no cognizance of the

_actual amount of Trimethol as such_--it merely indicates the relative

germicidal power of the Trimethol Syrup as sold.”

The preceding report shows that Trimethol Syrup has a phenol

coefficient of 1/10, and, assuming Trimethol Syrup contains the amount

of Trimethol declared, the substance Trimethol would have a phenol

coefficient of 8-1/3 instead of 40, as is claimed. According to Kendall

and Edwards’ method, the penetrability-germicidal value of the syrup is

equal to a 1 per cent. solution of phenol.

WALKER’S REPLY TO CRITICISM

The report of the bacteriologist was submitted to The Walker-Leeming

Laboratories for comment. The following reply was received from J. T.

Ainslie Walker:

(_May 22, 1917_) “In reply to your letter of the 15th inst., which

has just been placed before me on my return to town, I have to

inform you that the potent constituent of Trimethol Tablets and

Trimethol Syrup is not fully available as a bactericide until it

comes in contact with the pancreatic fluid.

“As you will see from the enclosed extracts from clinical reports,

the therapeutic value of Trimethol has been well established.

“As regards penetrability, no claim has ever been made for

Trimethol in this connection; and, as I pointed out in my original

paper (_American Medicine_, September, 1914), when referring to the

independent tests made by Dr. Frederick Sondern, ‘No attempt was

made to determine the bacterial content of the solid particles,

as in the opinion of the writer sterilization of the interior of

these particles is not only absolutely impossible, but wholly

unnecessary. The fact of the fluid contents of the canal being

sterile may be taken to indicate that the exterior of all solid

particles is in a like condition, and therefore harmless. It is

the organisms in the fluid portions only that produce the deadly

effects through the chemical substances they secrete; those in

the interior of the solid portions (_i. e._, as evacuated) may be

disregarded, as they are not available for good or evil.’

“I must confess to no little surprise on learning that your

investigator is still using the Hygienic Laboratory method of

determining phenol coefficients. I would respectfully suggest that

you call his attention to the critical comparison of the Hygienic

Laboratory and R.-W. Tests, which he will find in the enclosed

reprint from the _New York Medical Journal_ of March 11, 1916:

‘Instead of being an improvement upon the standard R.-W. Test,

the so-called Hygienic Laboratory Method is so defective as to

be wholly unreliable, and incapable of furnishing results of any

scientific or practical value whatever.’”

As to the statement that the potent constituent of Trimethol Tablets

and Trimethol Syrup is not fully available as a bactericide until it

comes in contact with the pancreatic fluid, attention is called to a

leaflet, which accompanies each bottle of Trimethol Syrup, that reads:

“Trimethol is insoluble in water, but when properly emulsified has

a Rideal-Walker co-efficient of 40; that is to say, it is 40 times

more efficient as a germicide than phenol (pure carbolic acid).”

The Trimethol Syrup which was used in the investigation, when mixed

with water produced an almost perfectly transparent solution, which

justifies the assumption that the proper physical conditions were

observed and that this objection is not well founded.

As regards the relation of pancreatic fluid to bactericidal

availability of Trimethol, there is little to say, other than that the

published statements in the advertising accompanying the packages make

no mention of this point. It would be interesting to know what, if any,

relation the pancreatic fluid has to this substance, in view of the

statement that it “has a Rideal-Walker coefficient of 40.”

The Trimethol “literature” does not throw light on the question, What

is the germicidal value of Trimethol Syrup as compared with phenol?

The only available method of determining the germicidal value of a

liquid disinfectant is to make a direct comparison of the substance

in question with phenol under similar conditions. Given parallel

conditions, not obviously prejudicial to the substance tested in

contrast to the standard solution, the results are comparable, and

furnish a basis for estimating the relative germicidal power of the two

substances. In the investigation, Trimethol Syrup and phenol were thus

compared.

As regards the contention that the bacteria within fecal masses are

harmless, this may be granted. But it must also be admitted that

these intestinal masses are constantly being reformed so that buried

micro-organisms do not remain in the interior. For this reason, the

determination of the penetrability coefficient of a germicide is

pertinent.

Regarding the respective merits of the old Rideal-Walker and the

newer U. S. Hygienic Laboratory method of determining the phenol

coefficient, the Rideal-Walker method was found to possess certain

drawbacks, and in an attempt to overcome these the “_Lancet_ Method”

was evolved; this method in turn was improved in the U. S. Hygienic

Laboratory and led to the United States Public Health Service Hygienic

Laboratory method for the determination of the phenol coefficient of

disinfectants (published in _Hygienic Laboratory Bulletin 82_). In

1913 this method was formally adopted by the Council for the valuation

of disinfectants or germicides of the phenol type, and the method is

now in general use for this purpose in the United States.[119] In this

connection Hiss and Zinsser may be quoted (Ed. 2, page 80): “The most

precise method of standardizing disinfectants is that now in use in the

United States Public Health Service.” Stitt, director of the United

States Naval Medical Schools, in his Practical Bacteriology, Blood

Work and Parasitology (Ed. 4, page 473) says: “In the United States

disinfectants are rated according to the Hygienic Laboratory Phenol

Coefficient.”

[119] Those who are interested in the relative merits of the

Rideal-Walker, the _Lancet_ and the Hygienic Laboratory methods for

the valuation of disinfectants, should read the following: Method

of Standardizing Disinfectants with and without Organic Matter,

J. A. M. A., Aug. 24, 1912, p. 667; Standardization of disinfectants,

Report of the Council on Pharmacy and Chemistry, J. A. M. A., April

26, 1913, p. 1316; Standardizing Disinfectants, J. A. M. A., Sept. 30,

1916, p. 883.

The Council adopted the recommendation of the Committee on Pharmacology

to the effect that the claims made for Trimethol are unsupported by

acceptable evidence. Accordingly, Trimethol and the pharmaceutical

preparations said to contain it--Trimethol Syrup, Trimethol Capsules,

and Trimethol Tablets--were held ineligible for New and Nonofficial

Remedies.--(_From The Journal A. M. A., Aug. 11, 1917._)

FERRIVINE, INTRAMINE AND COLLOSOL IODINE

Report of the Council on Pharmacy and Chemistry

E. Fougera & Co., Inc., New York, acting as agent for The British Drug

Houses, Ltd., London, advertise “Ferrivine,” “Intramine” and “Collosol

Iodine” to the medical profession. A circular entitled “Ferrivine, The

New Anti-Syphilitic Remedy” begins:

“FERRIVINE is the name given to ferric tri-para-amino-benzene

sulphonate. This iron compound was first prepared by Mr. J. E. R.

McDonagh, F. R. C. S., by whom it has been both biologically and

clinically tested. It is slightly soluble in water, the solution

having an acid reaction.

“INDICATIONS

“According to Mr. J. E. R. McDonagh’s researches, the phases of

the _Leucocytozoon syphilids_ are killed by the lipoid-globulin

molecules of the serum, which possess a stereochemical molecular

configuration homologous to those of the lipoid-globulin

molecules of the parasite. The process is one of absorption, a

chemico-physical reaction which is in part dependent upon the

supply of active oxygen. Active oxygen is formed directly by

oxidation processes and the peroxide necessary for its formation

directly by reducing processes. Oxidation is increased by metals

and reduction by non-metals. The non-metal which acts in the body

as the normal reducing agent is sulphur, hence the discovery of

Intramine (see separate pamphlet). The metal which acts in the body

as the normal oxidising agent, is iron, hence the discovery of

Ferrivine.”

A circular, “Intramine, a New Non-Toxic Compound for the Treatment of

Protozoal and Chronic Bacterial Diseases,” expounds Mr. McDonagh’s

ideas of the treatment of syphilis with Ferrivine and Intramine by

means of the oxidising action of Ferrivine and the reducing action of

Intramine and asserts:

“As the ultimate administration of oxidising and reducing agents

will benefit almost any infection, it may be said that Intramine is

indicated in all protozoal diseases, and in all chronic bacterial

diseases, especially in tuberculosis, presumably in leprosy and

possibly in malignant disease [cancer?]. To the administration of

Intramine there are no contraindications.”

We are also told that:

“Intramine is useful injected into the urethra.... In cases of

chronic urethritis and perifolliculitis ... invaluable as a local

application to chronic ulcers ...”

The Intramine circular includes a “Scheme of Treatment for Syphilis”

which advises, in addition to Intramine, Ferrivine or salvarsan,

mercury and iodids, the use of another proprietary called “Collosol

Iodine.” An inquiry addressed to Fougera & Co. in regard to the

character and composition of this preparation, brought the reply that

the firm had no knowledge of its identity.

This “scheme of treatment” is objectionable in that it advises the

“stock” treatment of a disease which demands individualization and

further in that whatever beneficial effects may result from the use

of mercury and iodid is likely to be ascribed to the preparations

“Intramine,” “Ferrivine” and “Collosol Iodine.”

The advertising for Ferrivine and Intramine sent out by Fougera & Co.

contains no experimental or clinical data on which an estimate of their

value may be based. Apparently in England, where these products were

originated, little has been published regarding them.

There is, however, one report which may be accepted as a carefully

controlled clinical trial. In the _Lancet_ (June 17, 1916, p. 1214)

L. W. Harrison, D.S.O., M.B., Ch.B.Glasg., and C. H. Mills, M.R.C.S.,

L.R.C.P.Lond., report on “The Effect of Ferrivine and Intramine on

Syphilis.” After briefly reviewing the theories which form the basis

of McDonagh’s proposed treatment of syphilis with his discoveries

“Ferrivine” and “Intramine” the authors point out:

“... that Mr. McDonagh’s biological discoveries ... have not been

publicly confirmed by any biologist of standing ...”

While:

“... eminent chemists have confessed themselves unable to

understand his chemistry.”

The authors explain:

“Recognizing that this might prejudice our practical tests of

Intramine and Ferrivine, we have taken particular care to guard

against their influence, cross-checking our observations and

submitting them to others for confirmation or otherwise.”

Harrison and Mills chose for a test three ordinary cases of secondary

syphilis, cases with well marked lesions, the clinical progress of

which could easily be watched and from which it was easy to obtain

specimens for microscopic examination. After a detailed account of

the three cases--which records grave conditions resulting from the

treatment and which shows the inefficiency of the drugs--they write:

“From the above account it will be seen that the local and general

reactions which follow the injection of these preparations are

by no means pleasant. In the case of Intramine the pain is

undiluted torture and lasts so for two or three days. One of us had

previously treated four cases with Intramine and the same local

reaction occurred in these. In two of them abscesses have burst

outwardly, one of which is still discharging necrotic débris, ten

weeks after the injection, and will take many more weeks to close.

In those cases where no abscess has yet burst it is easy to feel

by the gap in the muscles that considerable necrosis has occurred.

None of these effects can be ascribed to sepsis, as most rigid

aseptic precautions were taken. Further, particular care was taken

to make the injections strictly intramuscular. The constitutional

symptoms which follow immediately upon the injection of Ferrivine

are distinctly alarming, and such as would cause one to hesitate

before injecting this remedy into any but robust patients.”

Harrison and Mills estimate the therapeutic effects of these drugs thus:

“1. That Ferrivine entirely failed to cause _S. pallida_ to

disappear from the lesions of three well-marked cases of secondary

syphilis.

“2. After the failure of Ferrivine to cause the disappearance of

_Spirochaeta pallida_ from a mucous patch a single dose of 0.3 gm.

salvarsan effected this in 18 hours, and the patch, which had

hitherto been uninfluenced, had healed within 48 hours.

“3. Clinically we were unable to detect any influence of either

or both these compounds on syphilitic lesions, although each of

them was of the variety which heals in a week or ten days under

salvarsan treatment.

“4. Further syphilitic lesions appeared immediately after the

treatment in one of the two cases treated with both Ferrivine and

Intramine. A mucous patch appeared on one tonsil as well as further

syphilitic papules from which spirochetes were obtained. The other

case developed nephritis, with albumin and epithelial casts; which

was not present prior to the injections.”

While from these cases the obvious conclusion was drawn that Intramine

and Ferrivine “have no specific effect on early syphilis,” these

authors subsequently treated a case of tertiary syphilis with the

drugs. An Intramine injection caused pain for several days but did

not stop the progress of the disease. Ferrivine was then administered

“not without a feeling of grave responsibility” in view of their

previous experiences. They state that “the reaction which resulted

in this instance was the most severe” they ever experienced after

an intravenous injection of any of the antisyphilitic remedies with

which they had previously worked. It is stated that “for a period

of some minutes there was grave doubt as to the patient’s survival.”

After resuscitation the patient passed a disturbed night, and rigors

which ensued lasted until the following afternoon. The author’s report

that in this case also no clinical improvement occurred and that the

Intramine-Ferrivine treatment was replaced by a course consisting of

salvarsan, potassium iodid and mercurial inunction.

Ferrivine, Intramine and Collosol Iodine were declared inadmissible to

New and Nonofficial Remedies.--(_From The Journal A. M. A., Sept. 8,

1917._)

ESKAY’S NEURO PHOSPHATES

Report of the Council on Pharmacy and Chemistry

For the information of the profession the Council has prepared and

authorized for publication the following report on Eskay’s Neuro

Phosphates.

W. A. Puckner, Secretary.

Eskay’s Neuro Phosphates (Smith, Kline & French Co., Philadelphia) is

offered to physicians under the claims that it contains alcohol, 17 per

cent., and sodium glycerophosphate, 2 grains, calcium glycerophosphate,

2 grains, and strychnin glycerophosphate, 1/64 grain, in each

dessertspoonful. It is called a “Nerve Tissue Reconstructive,” and its

advertising claims are based on the discredited theories that certain

disorders are due to a deficiency of phosphorus in the nerve structure

of the body, and that glycerophosphates are assimilated more readily

than ordinary phosphates. This assumption was based on the knowledge

that the lecithins, which form a part of the nerve structure, contained

the glycerophosphate radical in the molecule. In line with this, Smith,

Kline & French Co. aver:

“Eskay’s Neuro Phosphates is of marked value in many acute and

chronic conditions, in nervous exhaustion following mental and

physical strain, neurasthenia, paralysis, anemia, tuberculosis,

marasmus, debility and wasting diseases generally, and the

nerve-weakness of the aged. It is particularly useful in

convalescence from acute diseases and in the nervous condition

following la grippe.”

In its report on “The Therapeutic Value of the Glycerophosphates” (The

Journal, Sept. 30, 1916, p. 1033) the Council pointed out that the

therapeutic use of the glycerophosphates was based on the assumption

that the inorganic phosphates cannot supply the body’s needs of

phosphorus or that the use of organic compounds “spared” the system

the necessity of making such synthesis. The report presented evidence

to show that the glycerophosphates are not absorbed as such, but

that they are split into inorganic phosphates before absorption. The

Council showed that there was convincing evidence that the animal

organism synthesizes its complex organic phosphorus constituents from

inorganic phosphates, and that organic phosphorus is of no more value

as a food than inorganic. Despite this the Neuro Phosphates advertising

makes use of the fallacious assumption regarding the action of the

glycerophosphates.

Pleading for the particular mixture represented by the proprietary, it

is asserted that:

“Sodium glycerophosphate is of special value in neurasthenia,

Addison’s disease, phosphaturia and phthisis.”

and that calcium glycerophosphate “is employed in bone fracture,

rachitis, tuberculosis and various wasting diseases.”

The phosphorus content of 1/64 grain of strychnin glycerophosphate is

ridiculously small. Yet it is asserted that this strychnin salt is of

superior value because it combines the effects of strychnin with a

“food-like form of phosphorus.” Eskay’s Neuro Phosphates has an acid

reaction which is capitalized, thus:

“Experiments have shown that the acid glycerophosphates are more

rapidly absorbed and are more efficient than the neutral salts.”

And as a further illustration of extravagant claims:

“As a glycerophosphoric acid in the form of lecithin is

normally present in spermatozoids, it is but natural that the

glycerophosphates should exhibit aphrodisiac effects (as has been

observed), but this result does not seem to obtain in all cases.”

Is this a clumsy attempt to exploit this “nerve phosphate” as a “lost

manhood” cure?

The Council held Eskay’s Neuro Phosphates ineligible for New and

Nonofficial Remedies because unwarranted therapeutic claims are made

for it and because the administration of strychnin, calcium, phosphate

and alcohol is not conducive to rational therapeutics, particularly

when such a mixture is marketed under a name which indicates but one of

its constituents.--(_From The Journal A. M. A., Sept. 29, 1917._)

K-Y LUBRICATING JELLY

Report of the Council on Pharmacy and Chemistry

Because of inquiries received, the Council has authorized publication

of the following report declaring K-Y Lubricating Jelly inadmissible to

New and Nonofficial Remedies.

W. A. Puckner, Secretary.

K-Y Lubricating Jelly (Van Horn and Sawtell, New York), originally

advertised as a lubricant for instruments and the hands, is now also

recommended as a therapeutic agent. If the claims for “K-Y” were

limited strictly to such effects as result from the purely mechanical

properties of a lubricant, it might be held that it would not come

under the purview of the Council. The preparation, however, while

introduced as a lubricant, is now offered for a broader field of use,

and the manufacturers make claims which are not supported by any

evidence available to the Council. Evidence the following, taken from a

circular that accompanies the package:

“K-Y allays smarting and burning at once through its pronounced

soothing and cooling effects, and thus makes an admirable dressing

for burns.”

“Many physicians make a practice of anointing the bodies of their

measle and scarlet fever patients with ‘K-Y,’ in this way affording

gratifying relief from itching and irritation, and effectively

preventing dissemination of infectious material.”

And this from another circular:

“I had one of the most troublesome cases of pruritus vulvæ that I

had ever seen. I guess I must have tried everything and the case

had been referred to me by another man, who had previously tried

everything, including cauterization. Well, one day I was examining

her, and of course K-Y on the speculum--the irritation seemed to

quiet down, and the following day she said she felt no effects from

it at all. Then later on, it returned, and I couldn’t imagine what

had done so much good, unless it could have been the lubricant, so

I told her to buy a tube, which she did. Every once in a while she

has a return of it slightly, but she just applies K-Y and clears it

all up.”

The manufacturers state that they do not know why K-Y is so soothing,

but suggest:

“Possibly the cooling action of the combination, and the effect of

the 4% boric acid contained, are factors that enter. Be all that

as it may, the fact certainly remains that oftentimes, after other

local measures fail, ‘K-Y’ lubricating Jelly gives relief.”

Elsewhere it is claimed to be germicidal, and to give relief in other

conditions, thus:

“Diabetic and uremic irritations, not only of the genitalia, but of

other parts, have been found fully as amenable as pruritus vulvae

to the soothing influence of ‘K-Y’ Lubricating Jelly, especially if

the previous application is removed with water every time a new one

is put on.”

The foregoing citations are obviously intended largely for the public,

and make it plain that “K-Y” Jelly is not in the class of nonmedical

and harmless external applications; on the contrary, these claims

tend to create the impression that the spread of measles and scarlet

fever can be _prevented_ in the stage of desquamation. To place

such statements in the hands of the patient supported by the tacit

endorsement of a prescription is to create a false and dangerous

sense of security and to lead to a failure to observe other and more

important means of preventing dissemination of these diseases.

The Council held K-Y Lubricating Jelly in conflict with Rules 1, 4, 6

and 10, and authorized publication of this report.--(_From The Journal

A. M. A., Sept. 29, 1917._)

ZIRATOL

Report of the Council on Pharmacy and Chemistry

Ziratol (Bristol-Myers Company, New York), in compliance with the

federal “insecticide law,” is declared to contain 32 per cent. water

and 30 per cent. glycerin as inert constituents. Regarding its active

constituents the manufacturer makes the following and meaningless

statement:

“Ziratol is prepared from Phenols of the Naphthalene series and

consists of a solution of such Phenols in a mixture of soap, water and

glycerin.”

In response to inquiry, the A. M. A. Chemical Laboratory examined

Ziratol and reported that its essential constituent appears to be

alpha-napthol,[120] and that it has, essentially, the following

composition by weight: Alpha-napthol 18 per cent., soap 20 per cent.,

glycerin and water sufficient to make 100 per cent.

[120] Alpha-napthol was also found to be the basis

of the nostrum Benetol. See The Journal, April 15,

1911, p. 1128.

A Ziratol advertising circular gives a tabulated report of germicidal

tests, said to have been made according to the method of the Hygienic

Laboratory of the U. S. Public Health Service. When this work was

done is not stated. According to these tests Ziratol possesses a

phenol-coefficient of 13.66. The claim that Ziratol is ten times more

efficient than carbolic acid (phenol) is evidently based on this report.

These claims of high germicidal value are contradicted by an

examination made for the Council. A specimen purchased in the open

market was examined independently by two operators, to determine the

Hygienic Laboratory phenol-coefficient. One observer found the phenol

coefficient to be 2.54. The other reported it to be 3.09. Evidently the

germicidal value of Ziratol is greatly exaggerated in the advertising

claims and, in fact, does not exceed that of the official compound

solution of cresol (Liquor Cresolis Compositus, U. S. P.) for which

a phenol-coefficient of about three has been established. (See New

and Nonofficial Remedies, 1917, p. 82.) The claim that Ziratol is

“the Universal Antiseptic and Germicide” is manifestly an unwarranted

exaggeration.

The referee in submitting this report to the Council recommended that

Ziratol be held in conflict with Rule 1 (secrecy of composition) and

Rule 6 (unwarranted and exaggerated claims). After the report had been

submitted, it was found that a new advertising circular, accompanying

a trade package, no longer contained the claim that “Ziratol is ten

times more efficient than Carbolic Acid.” The older circular made the

following statement:

“1. Strong Activity.--Compared with the bactericidal action of

Carbolic Acid by the method of the Hygienic Laboratory of the

Marine Hospital Service, ZIRATOL has the Carbolic Acid Coefficient

of more than TEN, that is, ZIRATOL is TEN times more efficient than

Carbolic Acid,--a strength unapproached by any other of its class.

ZIRATOL in dilution of 1:1400 kills the Typhoid Bacillus in 2-1/2

minutes, thus proving that it is strongly active even in very weak

solutions.”

The new advertising circular reads:

“1. Strong Activity--Extensive bacteriological investigations on

many pathogenic organisms, conducted in the Lederle Laboratories of

New York, prove conclusively the high bactericidal value of Ziratol

in extremely dilute solutions. (A copy of the complete report will

be mailed upon request.)”

In response to a request, the Bristol-Myers Company sent a copy of

the bacteriologic investigations of Ziratol, said to have been made

by the Lederle Laboratories. The organisms employed for these tests

were _Staphylococcus aureus_, _Staphylococcus albus_, _Streptococcus_,

Green pus bacillus, _B. coli_, and saliva. No tests are given with the

typhoid bacillus. The conclusion is reached that “in all the tests the

solutions of Ziratol have several times greater killing efficiency

than those of phenol.” The “coefficients” or comparative values which

can be calculated from the results after exposure of 15 minutes to the

disinfectants range from 2.0 to 4.0. This is in substantial accord

with the referee’s findings as regards the phenol-coefficient with _B.

typhosus_ as the test object. While the new advertising circular avoids

the former claim that Ziratol is ten times more efficient than carbolic

acid, in germicidal value, it still makes the unwarranted claims that

Ziratol is the “universal disinfectant.”

The Council declared Ziratol inadmissible to New and Nonofficial

Remedies (1) because its composition is secret (Rule 1); (2) because

the phenol coefficient, determined according to the method of the

Hygienic Laboratory, U. S. P. H. S., is not stated on the label (Rule

2); (3) because the label and the circular accompanying the trade

package advises its use by the public as a “vaginal douche” (Rule 3);

and (4) because the claim that Ziratol is the “universal disinfectant”

is exaggerated and unwarranted (Rule 6).

Before authorizing publication of the preceding report the Council

submitted it to the Bristol-Myers Company in order to give that company

the opportunity of revising its method of marketing Ziratol. In reply

the company enlarged on its withdrawal (on “our own initiative”) of

the claim that Ziratol had a phenol-coefficient of over ten when this

claim was shown to be incorrect “by authoritative sources.” One wonders

whether this is a euphemistic reference to the proceedings of the

federal authorities under the Insecticide Act against the Bristol-Myers

Company, just made public,[121] because of the false claims made for

the germicidal efficiency of Ziratol. This prosecution resulted in the

seizure and condemnation of two lots of this proprietary which had

passed in interstate commerce.

[121] U. S. Dept. of Agric., Insecticide and Fungicide Board, Service

and Regulatory Announcements, No. 16, issued Aug. 8, 1917. _No. 244_,

Misbranding of “Ziratol.” U. S. _v._ 100 bottles, more or less, of

“Ziratol”; consent decree of condemnation and forfeiture; product

ordered released on bond, p. 248. _No. 256_, Misbranding of “Ziratol.”

U. S. _v._ 936 bottles and 6 jugs of Ziratol, consent decree of

condemnation and forfeiture; product ordered released on bond, p. 260.

The Bristol-Myers Company in replying to the Council’s report made

no offer to declare the exact composition of Ziratol, to state the

actual phenol-coefficient, or to remove the other objections pointed

out in the report of the Council. In other words, the Bristol-Myers

Company has abandoned a definite but false claim of high germicidal

power--a claim which subjected the firm to federal prosecution--and

has substituted therefor indefinite statements which do not define the

actual germicidal efficiency of Ziratol.--(_From The Journal A. M. A.,

Oct. 6, 1917._)

GONOSAN

Report of the Council on Pharmacy and Chemistry

The Council has adopted the following report on Gonosan and authorized

its publication.

W. A. Puckner, Secretary.

Gonosan (Riedel and Company, Inc., New York City) comes in the form of

capsules, each said to contain 5 minims of a mixture composed of oil of

sandalwood 80 per cent., and 20 per cent. of alpha- and beta-resin of

kava, isolated by a patent process. The mixture, as the name implies,

is intended for the treatment of gonorrhea.

This proprietary preparation was under consideration by the Council at

various times from 1905 to 1910. During this time, the Council agreed

to accept the preparation if the suggestive name was changed, the

therapeutic exaggerations abandoned, and the drug kava admitted to New

and Nonofficial Remedies. The name was not changed, the other questions

were left open, and the preparation was not accepted.

Recent and more objectionable advertising of Gonosan makes it advisable

for the Council to take action and to publish a report. The tone of

this advertising is reflected by the following quotation from a recent

advertising circular:

“The old-established balsamic treatment of gonorrhea, for some

years neglected in favor of the local injection of organic silver

and other germicidal salts, has, with the increasing knowledge

and attention paid to the composition and purity of the balsams,

regained to a large extent the confidence formerly reposed in them.

“It may now be said that the combined treatment with local

injections and internal administration of natural balsamic products

completely dominates modern gonorrheal therapy.”

Any one conversant with current medical literature and practice would

stamp these statements as misleading exaggerations. The balsams,

oleoresins and volatile oils may have some value as minor adjuvants

in the treatment of gonorrhea, but that is all. The position in this

respect has not changed materially in recent years. These agents do not

have a value equal to that of local treatment, as the quoted statement

implies.

The claims made for Gonosan might with equal force be made for oil of

santal alone. Kava kava, the other constituent, belongs to the pepper

family; it had a temporary vogue some two or three decades ago, but has

failed to maintain a place. It has never been recognized officially.

There is no scientific evidence that it has any value either alone or

as an adjuvant to sandal oil. The “clinical reports” quoted in the

advertising circulars, rather curiously, nearly all date back ten

years or more, viz., to a period when the attitude of the profession

toward proprietary remedies was less critical than it is now. It would

be interesting to know whether these authors still adhere to their

opinion, or whether any of them have subsequently had experiences

similar to that of a correspondent who wrote:

“Gonosan, at my hands, did not prove to be of more essential

value in the treatment of gonorrhea than any other sandalwood oil

preparation. The various claims made for Gonosan, that it possesses

sedative and anesthetic properties, that by its continuous use the

urethral discharge disappears more rapidly and that, if combined with

appropriate diet and rest, it is liable to prevent complications, are,

according to my experience, not corroborated by actual results.”

The only experimental work quoted in support of Gonosan, that of Pohl,

is not convincing. The doses that Pohl found necessary to influence

experimental purulent pleurisy makes it impossible to transfer his work

to the clinic. (He found a dosage of oil of santal corresponding to an

ounce per day, for man, inefficient; positive results were obtained

only with 2 ounces per day.)

In order to learn the estimate placed on the therapeutic value of the

“balsams,” an inquiry was sent to the authors of the papers presented

to the section of Genito-Urinary Diseases at the recent meeting of the

American Medical Association in New York. The inquiry read:

“_Dear Doctor_:--An advertising circular for Gonosan ‘Riedel’ which is

now being distributed begins thus:

‘The old-established balsamic treatment of gonorrhea, for some

years neglected in favor of the local injection of organic silver

and other germicidal salts, has, with the increasing knowledge

and attention paid to the composition and purity of the balsams,

regained to a large extent the confidence formerly reposed in them.’

‘It may now be said that the combined treatment with local

injections and internal administration of natural balsamic products

completely dominates modern gonorrheal therapy.’

“Is the statement correct that the combined treatment with local

injections and internal administration of natural balsamic products

completely dominates modern gonorrheal therapy? Your reply to the above

will be appreciated by the Council.”

Seventeen replies were received. They bear out the position that

has been outlined. Only one writer considered the statement even

approximately justified, and this in the sense that “the majority

of cases receive no other treatment” than a combination of local

applications and systemic medication. Another stated that, “in a

general way their statement is true though a trifle too sweeping,” and

then added that the field of the balsams is rather restricted. With

the exception of these qualified endorsements the remaining (fifteen)

replies characterized the statement as incorrect and misleading. The

replies are a valuable contribution to the status of the “balsam”

treatment of gonorrhea, and extracts of them are appended to this

report.

It is recommended that the Council declare Gonosan inadmissible to

New and Nonofficial Remedies, because the therapeutic claims are

exaggerated (Rule 6); because there is no evidence that the combination

of kava resin with oil of santal is superior to oil of santal alone

(Rule 10); and because the therapeutically suggestive name is conducive

of indiscriminate and unwarranted use of the preparation both by the

profession and the public (Rules 4 and 8).

Appendix

The extracts from replies received to the inquiry above referred to,

follow:

Dr. B., Penn., wrote:

“In my practice I have found that local injections are very

valuable in the treatment of gonorrhea, but I have never found that

the internal administration of natural balsamics dominated modern

gonorrheal therapy; while it is an aid, I consider the quoted

statement to be very erroneous.”

Dr. F., D. C., wrote:

“While it is doubtless true that acute urethritis, gonorrheal, is

now generally treated by local injections of solutions of organic

silver salts, and that santal oil is often used, it is not true,

as one would infer from the quotation, that the balsams are now

considered more efficacious than they were formerly. So far as I

know they have not lost or regained anything during the past dozen

years in the way of confidence reposed in them. The indications for

their use is very definite and very limited.”

Dr. B., Ga., wrote:

“... In recent years I have almost abandoned the use of balsams,

etc., in the treatment of gonorrhea. Patients, who are properly

treated otherwise, seem to get along as well without such drugs

as with them, in fact apparently better for they have no gastric

disturbance. It is important for patients to drink freely of

water and when so doing the balsams are so diluted that I cannot

conceive of their doing much good. Formerly my patients often lost

weight during the treatment of gonorrhea; now, without balsams and

with plenty of water, they usually gain in weight.”

Dr. S., Mich., wrote:

“... we believe that in a general way their statement is true

though a trifle too sweeping. We do not ordinarily use the

balsams in uncomplicated anterior urethritis. We do however, find

indication for their administration in from sixty to seventy five

per cent. of all cases of acute gonorrhea at some time during the

course of the disease.”

Dr. L., Mo., wrote:

“I would say that the statement that, ‘The combined treatment with

local injections and internal administration of natural balsamic

products completely dominates modern gonorrheal therapy,’ is far

from representing the facts. While the balsamics may occasionally

have an indirect soothing effect on the mucous membranes involved,

the dominant factor is local treatment, aiming at disinfection and

restoration to normal of the inflamed tissues.”

Dr. R., Mich., wrote:

“Regarding your request although I am willing to reply it is

difficult to do so because if I should do so in the affirmative

that could apply only to certain acute cases without complication

of any kind and such cases are rare. In such, however, the

advertiser is not far from right--since vaccine therapy has proven

absolutely worthless we must fall back on antiseptics in acute

urethritis when there are no objections to such treatment ...”

Dr. K., Ill., wrote:

“I am under the impression that the internal administration of

balsamics is used only when complications arise, such as acute

posterior urethritis. Personally I use the balsamics very, very

rarely. From my observation, however, I am led to believe that many

men still use internal drugs in the treatment of gonorrhea, and

during the past few years, I should say the use of hexamethylenamin

has been on the increase, and the use of the balsams on the

decrease. I do not believe that hexamethylenamin is of any value

in the treatment of gonorrhea, and am simply citing this as my

observation of the widespread use of this drug in the treatment of

gonorrhea.”

Dr. T., Penn., wrote:

“... I believe that more men use salol or hexamethylenamin, or no

urinary antiseptic whatsoever, than use the balsamics.”

Dr. B., Ind., wrote:

“... The only systemic treatment that is considered necessary today

is rest, plenty of water and neutralize the acidity of the urine

with bicarbonate of soda or some sodium salt.”

Dr. Y., Mass., wrote:

“Sandal wood oil during the acute stage of gonorrhea certainly tends to

make the patient more comfortable and undoubtedly does lend some (tho I

believe slight) gonococcidal action. That it plays any _considerable_

part in actual cure I think is doubtful. The statement as quoted

is true in so far as it states that local treatment plus internal

medication with a balsam comprises most of the modern treatment of

gonorrhea but it is grossly misleading in that it lets one draw the

inference that the balsam plays a large if not the principal part.”

Dr. H., New York, wrote:

“For a period of at least three years in my hospital, dispensary

and private practice, I conscientiously tried out most of the

balsamics on the market (including Gonosan, which I favored for

some time) both alone, and combined with local injections. As

a result of this study, I have come to the conclusion that the

balsamics have little, if any value in the treatment of gonorrhea.

During the past few years I have relied almost entirely on local

therapy, and seldom prescribed any of the balsams in my private

practice, certainly in not more than 5 per cent. of the cases.

My results I find are just as satisfactory, and my patients

appreciate the fact that they are not loaded up with disagreeable

medication. Instead of the balsamics, I am using sodium bicarbonate

more and more, and feel convinced that the proper use of this drug

is of more value than all of them combined.”

Dr. K., Cal., wrote:

“The statement that the combined treatment with local injections

and internal administration of natural balsamic products completely

eliminates modern gonorrheal therapy, would at present not be

justifiable even with reference to the initial or acute stage

of gonorrhea, while in the subacute and chronic forms of the

disease local injections and balsams play an almost insignificant

rôle as compared with various other recognized therapeutic

measures.”--(_From The Journal A. M. A., Oct. 13, 1917_).

ALCRESTA IPECAC

Report of the Council on Pharmacy and Chemistry

The Council has adopted the following report and authorized its

publication.

W. A. Puckner, Secretary.

In 1915 Alcresta Ipecac Tablets (Eli Lilly and Co.) were admitted

to New and Nonofficial Remedies as a preparation of ipecac that

is insoluble in the stomach but soluble in the intestines. It was

supposed that this property would permit the administration of ipecac

without the accompanying nausea and vomiting, and that this would be

of especial advantage when using the drug in amebic dysentery. The

systemic effects, of course, would be those of ipecac.

More recently, the manufacturers of Alcresta Ipecac have been advising

its use in conditions which were not contemplated by the Council when

the preparation was accepted for New and Nonofficial Remedies. They

now claim that ipecac alkaloids have been shown to be useful in the

treatment of typhoid fever, flatulence, diarrhea and constipation

and that Alcresta Ipecac has these properties. Such a statement

is misleading. While it is true that at one time ipecac was used

promiscuously against “flatulence, diarrhea and constipation” there

never has been and is not now any scientific evidence of its efficiency

in such conditions except, of course, in diarrhea of the amebic type.

As to the alleged usefulness of ipecac in typhoid fever: This has not

even the sanction of tradition and the claim certainly should not be

accepted until there is strong evidence to support it.

The advertising matter on Alcresta Ipecac also contained statements

to the effect that ipecac alkaloids have a demonstrated usefulness

in pyorrhea. Such an unequivocal statement is unwarranted. In spite

of the enthusiastic advocacy, in the past, of ipecac alkaloids as

a specific in pyorrhea alveolaris the preponderance of scientific

evidence indicates that ipecac is of questionable value in this

condition. Neither is there any substantial evidence to warrant the

claim that ipecac alkaloids, when absorbed through the intestines, are

demonstrably useful in amebic infections of the tonsils.

The reputation of the best drugs, whether unofficial or official,

is bound to suffer if extravagant claims for them are permitted to

go unchallenged. The referee of the Council, therefore, believed it

necessary to call the attention of the manufacturers of Alcresta Ipecac

Tablets to the statements made for the product and suggested that they

submit evidence to substantiate the claims. This the manufacturers have

refused to do. Their attitude in the matter, as well as their attitude

toward the Council’s work is expressed in the following letter:

“Responding to your letter of March 10th, we beg to suggest that

literature covering the different matters at issue are readily

available to your referee, and all statements emanating from us are

made advisedly.

“If you cannot satisfy yourselves that this preparation is a

scientific product, ethically advertised, and a desirable advance

in therapeutics, you can only delete it from your next issue of New

and Nonofficial Remedies.”

It is to be regretted that Eli Lilly and Co. refuse either to withdraw

or modify their claims or to substantiate these claims by scientific

evidence. The statements as they stand are exaggerated, misleading

and harmful. As such they conflict with Rule 6 of the Council and

necessitate the omission of Alcresta Ipecac from New and Nonofficial

Remedies. The referee recommended the adoption and publication of this

report.--(_From The Journal A. M. A., Oct. 20, 1917._)

IODEOL AND IODAGOL

Report of the Council on Pharmacy and Chemistry

Iodeol and Iodagol (formerly called Iodargol) are products of Viel and

Company, Rennes, France, widely advertised in this country by David B.

Levy, Incorporated, New York. The claim made for both preparations is

that they depend on “colloidal iodin” for their action. They are put up

in a number of forms, for instance:

“Iodeol Ampoules each containing 1 c.c. (20 centigrammes colloidal

iodin in an oily vehicle).”

“Iodeol External, containing 50 per cent. colloidal iodine.”

“Iodagol Ampoules, each containing 2 c.c. (50 centigrammes

colloidal iodine in an oily vehicle).”

The claim is, that, the iodin being in the colloidal state, it has the

properties of elementary iodin and thus the preparations may be used in

concentrations and under conditions which would make the use of free

iodin impossible. The products have been extensively and extravagantly

advertised for use in a wide range of conditions. Thus Iodeol has been

proposed in the treatment of:

“Pulmonary Tuberculosis”

“Laryngeal Tuberculosis,”

“Glandular Tuberculosis”

“Tuberculosis of the Bones”

“Pneumonia, Broncho-pneumonia, and Congestive Conditions”

“Whooping Cough, Influenza, Asthma”

“Typhoid Fever”

“Syphilis”

“Obesity.”

Iodagol, which is for external use, has been advised in the treatment

of:

“Gonorrhea and its Sequelæ”

“Cystitis”

“Tetanus”

“Wounds complicated by gaseous gangrene”

“Burns”

“Old Suppurations, ulcers, abscesses, etc.”

“Articular rheumatism”

“Abscess Alveolar”

“Pyorrhea Alveolaris”

“Stomatitis (Canker-Sores).”

Nearly two years ago the American agents requested the Council to

consider Iodeol and Iodagol for admission to New and Nonofficial

Remedies. The information submitted in regard to their character and

composition was vague and indefinite, the pharmacologic information

practically nil and the clinical data as voluminous as it was

unconvincing.

On the basis of chemical, pharmacologic, bacteriologic and clinical

investigation carried out under the direction of the referee and a

study of the submitted evidence, the referee reported:

1. Iodeol and Iodagol do not contain the amount of iodin claimed.

2. The iodin is not present as elementary iodin, but instead the

preparations behave similarly to the well-known organic iodin compounds

such as iodized fats.

3. The therapeutic claims made for the preparations are exaggerated and

unwarranted.

In view of his findings he recommended that Iodeol and Iodagol be

declared inadmissible to New and Nonofficial Remedies for conflict

with Rules 1 and 2 (misleading statements regarding composition and

identification) and Rule 6 (unwarranted therapeutic claims). The

Council adopted the recommendation of the referee, directing inclusion

of the full report in the annual Council reports after submission to

the manufacturer, and recommending publication of an abstract of this

report in The Journal.

This report was brought to the attention of the American agent, David

B. Levy, Inc., and through them to the French manufacturers, E. Viel

and Company. The manufacturers have intimated that they will not file

a reply to the report. The firm of David B. Levy, Inc., has decided to

sever its connection with these products and to discontinue their sale.

W. A. Puckner, Secretary.

Summary of Referee’s Report

Iodeol and Iodagol were submitted to the Council nearly two years ago

as “electro-colloidal iodine” and with the claim that they produced

all the antiseptic and other effects of ordinary iodin without any

of its side actions. The referee has done much work on the subject,

conducted a large amount of correspondence and has contended with

long delays. He feels that the consideration of these products should

be brought to a conclusion and accordingly he submits this report of

their consideration. The following is a summary of the report, which is

appended:

_I. Discrepancy in Iodin Percentage._--The examination at the Chemical

Laboratory of the American Medical Association, as well as that of the

referee, shows that the various samples of Iodeol and Iodagol examined

contained a little less than one-half of the total iodin claimed. These

facts were reported to the American agent. After a lengthy delay a

reply was received which presented a double excuse: (1) that the full

amount of iodin had been added, whatever had become of it later; (2)

that the claims were made for “colloidal iodin” and that this is not

elementary iodin in the colloidal state, but a preparation of iodin

containing only 50 per cent. of real iodin. Neither explanation can be

taken seriously, as they are obvious quibblings. The referee concludes

that the preparations are falsely labeled as to iodin content.

_II. Nature of the Iodin Compound in Iodeol and Iodagol._--In the

information sent the Council, Iodeol and Iodagol were defined as

“A suspension of electro-chemical colloidal iodin in a vehicle of

purified oil.” Numerous inquiries have failed to elicit more specific

information from the manufacturer or his agent. The statement of

composition can mean only that the preparations contain free iodin (but

in colloidal form) suspended in oil. No evidence to substantiate this

claim has been submitted. (There is evidence that the preparations

contain colloidal particles, but it does not indicate if this colloidal

material is iodin, or a combination of iodin or indeed whether the

colloidal component contains any iodin.) The recent statements of the

agent seem to concede that what they call “electro-colloidal iodin”

contains only about 50 per cent. of real iodin, in other words that it

is not “colloidal iodin” at all, but a mixture or combination of iodin

with some other unnamed substance. This, of course, is something very

different.

Certain results reported from the American Medical Association’s

Chemical Laboratory suggest that the so-called “colloidal iodin”

of Iodeol may be a combination of iodin with a volatile oil. The

investigations of the referee indicate that the iodin exists in a

rather resistant form or combination behaving altogether differently

from ordinary free iodin, and rather resembling the behavior of iodin

substitution products, such as iodized fats or phenols. Briefly

then the recent admissions of the agents indicate that Iodeol does

not contain “colloidal iodin” in a chemical sense, and there are

indications that it does contain its iodin in a rather firm (chemical)

combination.

_III. Chemical Properties of Iodeol._--From a study of different

specimens of Iodeol, the referee concludes that fresh specimens contain

no free iodin and that old ones contain small amounts as a result of

decomposition. Iodeol has the solubility characteristics of fats and

fat-like compounds. The examination, as a whole, shows that Iodeol

contains a peculiar and rather resistant form or combination of iodin.

There is nothing in the chemical data that suggests that it could act

differently from ordinary iodin compounds, such as iodized fats. It

would not act as ordinary iodin.

_IV. Pharmacologic Data._--The pharmacologic statements which were

submitted were loose and apparently meaningless or misleading. In

reply to questions submitted by the referee, the manufacturer finally

had some work done and submitted a report by Jean Laumonnier. The

referee was unable to confirm some of this work, and as a whole it

does not appear materially to elucidate the action of Iodeol. From a

consideration of the submitted evidence, and as a result of his own

work, the referee concludes that Iodeol does not behave like elementary

iodin; it does not coagulate proteins and therefore is not irritant. It

is presumably absorbed, but quite probably after chemical change; it is

changed into iodid and, like organic iodids, is excreted somewhat more

slowly than when inorganic iodids are administered, but the difference

does not appear important.

_V. Antiseptic and Bactericidal Action._--Elementary iodin is

considered a fairly powerful agent in these respects. The activity

is presumably due to changes in the proteins, etc., of the bacteria,

analogous to the effects which produce pain, irritation and necrosis of

the tissue cells. Since the latter effect is not produced by Iodeol,

it seems highly improbable, if not impossible, that it should act on

bacteria like elementary iodin. It is entirely unjustifiable to credit

the known antibacterial qualities of ordinary iodin to “colloid” iodin.

This misrepresentation is especially prominent in the circular “Notable

New Therapeutic Agents,” as will be seen, for instance, from the

following citations:

“Iodine has long been universally recognized as an antiseptic of

extraordinary potency. Not only is it rapid and certain in its

germ-destroying action, but it also possesses an attribute denied

many other antiseptic agents, namely, the power to penetrate and

impregnate the tissues. Other antiseptics, as is well known, act on

the surface epithelium only.”

“According to Kinnaman (J. A. M. A., Aug. 26, 1905), iodine is far

superior to bichloride of mercury, a two per cent. solution killing

streptococcus pyogenes in two minutes. Iodine does not coagulate

albumin, and is very penetrating.”

The citations imply that this “colloidal iodin” of Iodeol and

Iodagol acts as an antiseptic like ordinary iodin, except that it is

claimed to be more efficient by “diffusing” more readily. This is

entirely unjustified and misleading. If Iodeol and Iodagol are really

antiseptic, they must act by some other mechanism than that through

which elementary iodin acts, and such antiseptic action would have to

be demonstrated by direct observation and not assumed from the known

action of free iodin.

Antiseptic and bactericidal effects are easily estimated by laboratory

methods. Yet no evidence on this point appeared to have been available

until the Council called for this. Laumonnier then carried out some

experiments which were in turn submitted to bacteriologic control. The

bacteriologist failed to obtain any results with some of the tests, and

considered the other data of little value.

The claim that Iodeol and Iodagol have the antiseptic and bactericidal

action of free iodin lacks proof and must be considered unwarranted and

misleading in the extreme.

_VI. Clinical Trials._--The manufacturers and agents of Iodeol

presented many letters from physicians; but few, if any, of these gave

evidence of careful, critical, controlled observations. They could not,

therefore, be considered as acceptable evidence. The more important

claims, letters and published papers, however, were submitted to

clinical specialists collaborating with the Council, with the request

that they examine these and conduct some clinical trials, if they

considered it advisable. The results obtained in these preliminary

trials did not appear sufficient to warrant further experimentation.

From a consideration of the evidence presented, the referee concludes

that the claims made for Iodeol and Iodagol are unwarranted,

exaggerated and misleading. He recommends that Iodeol and Iodagol be

declared ineligible for New and Nonofficial Remedies for conflict

with Rules 1 and 2 (misleading statements as to composition and

identification) and with Rule 6 (unwarranted and misleading therapeutic

claims). He further recommends that the Council authorize publication

of the preceding summary of the consideration of Iodeol and Iodagol

in The Journal and inclusion of the full report in the annual Council

reports after submission to the manufacturer.--(_From The Journal

A. M. A., Nov. 17, 1917._)

CAPSULES BISMUTH RESORCINOL COMPOUND NOT ADMITTED TO N. N. R.

Report of the Council on Pharmacy and Chemistry

In response to inquiries received, the Council took up the

consideration of Capsules Bismuth Resorcinol Compound (The Gross Drug

Company, Inc., New York City). The label, sent by the Gross Drug

Company, bore the following:

CAPSULES

BISMUTH RESORCINOL COMPOUND

Bismuth Subgallate 2 grs.

Resorcinol 1 gr.

Beta Naphthol 1/2 gr.

Creosote (Beechwood) 1 m.

This combination is of acknowledged value

in reducing the value in reducing the intes-

tinal putrefaction and fermentation, allaying

the pain and discomfort of flatulent conditions

in the intestinal tract.

DOSE.--One or two capsules before or after meals

repeated in two hours if necessary.

The Gross Drug Company, Inc.

20 Laight Street, New York

The Council held this preparation inadmissible to New and Nonofficial

Remedies or the Appendix, because (1) the claim “acknowledged value in

reducing the intestinal putrefaction and fermentation, allaying the

pain and discomfort of flatulent conditions in the intestinal tract” is

an unwarranted, exaggerated and misleading claim of therapeutic value

(Rule 6); because (2) the name does not indicate the identity of the

bismuth salt contained in the capsules, nor declare the presence of

betanaphthol and creosote (Rule 8); and because (3) the combination

of bismuth subgallate, resorcinol, betanaphthol and creosote in fixed

proportions is irrational (Rule 10).--(_From Reports of Council on

Pharmacy and Chemistry, 1917, p. 139._)

DIXON’S TUBERCLE BACILLI EXTRACT AND DIXON’S SUSPENSION

OF DEAD TUBERCLE BACILLI

Report of the Council on Pharmacy and Chemistry

New and Nonofficial Remedies, 1917, contains general descriptions

of Dixon’s Tubercle Bacilli Extract and Dixon’s Suspension of Dead

Tubercle Bacilli; the products of these manufactured by the H. M.

Alexander Company being listed as dosage forms. It having become

necessary to omit the preparations of the Alexander Company (see page

138) the referee recommended that the general articles of “Dixon’s

Tubercle Bacilli Extract” and “Dixon’s Suspension of Dead Tubercle

Bacilli” also be omitted. He reported that no other firm appears to

be marketing these products and that they had not been shown to be of

special value.

The Council accepted the recommendation and directed the omission as

proposed. In accordance with the procedure of the Council, these have

been transferred to the annual Council Reports for reference and appear

below.

W. A. Puckner, Secretary.

=Dixon’s Tubercle Bacilli Extract.=--An extract of tubercle bacilli

dissolved in normal saline solution. (See “Fluid of Dixon,” _Medical

News_, Jan. 17, 1891.)

=Dixon’s Suspension of Dead Tubercle Bacilli.=--A suspension in

physiologic salt solution of dead tubercle bacilli which have

been defatted by prolonged treatment with alcohol and ether. (See

“Possibility of Establishing Tolerance for Tubercle Bacilli,” _Medical

News_, Oct. 19, 1889.)--(_From Reports of Council on Pharmacy and

Chemistry, 1917, p. 140._)

FORMOSOL

Report of the Council on Pharmacy and Chemistry

Sunshine’s Formosol (The Formosol Chemical Company, formerly the

Sunshine Chemical Company, Cleveland, Ohio) is claimed to contain

18 per cent. formaldehyd in a solution of soap. It is therefore

very similar to Veroform Germicide which was deleted from New and

Nonofficial Remedies because of the low phenol coefficient reported by

the Hygienic Laboratory of the United States Public Health Service (The

Journal, Nov. 22, 1913, p. 1920.) The Council voted that in view of the

Hygienic Laboratory’s finding that formaldehyd has a low germicidal

value, the manufacturers of Formosol be required to produce definite

evidence of the degree of germicidal value for this product.

In submitting the preparation to the Council, it was claimed that

Formosol had “all properties peculiar to Formaldehyde.” This

conservative tone was, however, not maintained in the form-letters

submitted. These contain the following unwarranted statements:

“As the name implies, FORMOSOL is a formaldehyde preparation, which

embodies all the innate antiseptic merits and eliminates all the

ill features of the world’s greatest disinfectant.”

“The elimination of all the destructive elements and the

incorporation of all the established therapeutic virtues of

formaldehyde, have been scientifically blended in FORMOSOL.”

“FORMOSOL is unique in the sphere of antisepsis because of its

peculiar healing properties as diametrically opposed to irritation

to the tissue of mucous membrane.”

“FORMOSOL may be used for the thousand niceties of modern

antisepsis, but is _specific_ in Gynecology and Obstetrics and is

indicated in Dermatology.” [Italics not in original.]

“The constant use of FORMOSOL is to develop a habit sympathetic to

ethics.”

“To prescribe FORMOSOL is a great step toward Personal Hygiene, a

_duty of the medical fraternity_ to the laity.” [Italics not in

original.]

The trade package recommends the use of Formosol “for cuts, wounds,

ulcers, abscesses ...” This is a conflict with Rule 4. The Council held

Formosol in conflict with Rules 4 and 6, and advised the manufacturers

that Formosol is refused admission to New and Nonofficial Remedies

until they submit evidence establishing the degree of antiseptic and

germicidal efficiency, and justify the quotations listed above; or

until these and any other existing conflicts with the Rules have been

removed.

After submission of this report to The Formosol Chemical Company the

Council authorized its publication.--(_From Reports of Council on

Pharmacy and Chemistry, 1917, p. 145._)

IODOLENE, A SOLUTION OF IODIN IN LIQUID PETROLATUM,

INADMISSIBLE TO N. N. R.

Report of the Council on Pharmacy and Chemistry

The Council was asked to consider a solution of iodin in liquid

petrolatum, said to be prepared from Gulf Coast petroleum by a special

process. It was to be marketed as “Iodolen” provided the Council

found the preparation admissible to New and Nonofficial Remedies. The

preparation was claimed to contain over 1.5 per cent. free iodin. The

following claims were made:

“It is less irritating in its use on the skin, or in wounds.” “Will

kill pathogenic micro-organisms present.” “Is a suitable medium for

cell proliferation.” “Will penetrate a useful distance into the

walls of a wound.” “Facilitates an easier, less painful and better

method of dressing wounds or ulcers.”

Examination in the American Medical Association Chemical Laboratory

showed a submitted sample to contain 1.32 per cent. free iodin and

to emit a strong odor of hydrogen sulphid. A specimen of liquid

petrolatum, said to be composed chiefly of hydrocarbons of the

naphthene series, after saturation with iodin at room temperature was

found to contain 1.42 per cent. free iodin. Another specimen of liquid

petrolatum, said to be composed chiefly of saturated hydrocarbons,

after saturation at room temperature was found to contain 1.30 per

cent. free iodin.

The preparation having been shown to be an unoriginal, simple

solution of iodin in liquid petrolatum, the Council declared the name

“Iodolene” unacceptable (Rule 8) and the therapeutic claims made for

the preparation unwarranted (Rule 6).--(_From Reports of Council on

Pharmacy and Chemistry, 1917, p. 148._)

KALAK WATER

Report of the Council on Pharmacy and Chemistry

The following report, submitted by a member of the Council’s committee

on chemistry, was endorsed by the committee and adopted by the Council:

Kalak Water, sold by the Kalak Water Company, Inc., New York, is an

artificial mineral water said to be made by adding certain salts to

carbonated, distilled water and supersaturating with the gas under

pressure. Such merit as it may possess by virtue of sodium bicarbonate

and sodium phosphate is quite insufficient to warrant the extravagant

claims made in the advertising pamphlets.

According to the analysis furnished, the water contains, in 1,000,000

parts (milligrams per liter) the following:

Sodium carbonate 4049.0

Sodium phosphate 238.5

Sodium chloride 806.3

Calcium carbonate 578.2

Magnesium carbonate 48.9

Potassium chloride 47.9

Among the many misleading statements found in the advertising pamphlet

bearing the title “A Brief for Physiological Alkalescence” these may be

quoted:

“The calcium content of Kalak is over 100% greater than ever before

placed in solution in any vehicle, a fact of supreme importance

when the unique alkalinizing power of the alkaline salts of this

metal is considered; the ratio of calcium metabolism to its

enormous waste in pregnancy, the diseases of infancy and childhood

and the rapidly growing group of ‘acidoses’ make its availability

in Kalak of double value.”

The first part of this statement is untrue; the last part is muddled

and without much meaning. Evidently the “acidosis” fad is to be

overworked as was the old “uric acid diathesis,” of unsavory memory.

Again this:

“One of the most important characteristics of Kalak is the close

approximation of its formula to the correlation of the contained

salts as they occur in the human body, together with its freedom

from salts foreign to the human economy. Another is its almost

unbelievable palatability, considering its high degree of

alkalinity, it being eleven times greater than any other known

mineral water, artificial or natural.”

These statements are false. The salts dissolved here bear no

discernible relation to the needs of the body, as disclosed by the

composition of the blood or solid tissues or as shown by the character

of the urinary excretion. The last statement concerning the high

alkalinity is neither clear nor accurate. Then, this warning and remedy:

“It seems to be an unappreciated fact that the degree of urinary

acidity, checked with the acidity of the saliva, is in direct ratio

to the existing acid toxemia, and a urine acid to methyl red should

be the signal for immediate and adequate alkalinizing treatment....

“Startling clinical results have been observed by physicians who

have used Kalak thoughtfully and sufficiently in the more serious

types of acidosis associated with diabetes, nephritis, rheumatism,

gout and the acute infections. There is also evidence of its good

effect in acute alcoholism and the respiratory edemas; in fact a

certain few have hailed Kalak as a possible solution of the annual

hay fever problem. Of perhaps supreme importance, however, is the

use of Kalak throughout pregnancy as preventive medicine against

the inevitable ‘toxemia of pregnancy.’”

Also this:

“Kalak has accomplished certain unexplainable things for the

diabetic and nephritic, and if, in future years, diabetes and

nephritis should prove to be constitutional diseases, based upon

functionation or its lack, Kalak therapy, the embodiment of

physiological alkalescence may come into its own, for if acidity

retards, alkalinity must normalize functionation.”

It is not necessary to quote further. In order to insure that everyone

will recognize the great need of Kalak it is advised to test the urine

for acidity by means of a group of indicator solutions sent out to the

physicians. Methyl red is one of these and any urine showing an acid

reaction with this is said to be open to suspicion. Paranitrophenol is

another of the indicators and the explanations given of the behavior of

the two and the conclusions to be drawn are questionable. The methyl

red solution furnished is too concentrated for proper use and perfectly

normal urines from normal individuals have given a rather marked color

with it. This indicator gives some color at [H+] = 1.2 × 10^{-6} and a

strong reaction at 3 × 10^{-3}. To condemn a urine on such a finding is

entirely unwarranted.

Sodium bicarbonate is the main constituent of the water. The value

of the phosphate in such a combination, with so much calcium, is

problematical. In case an alkaline reaction in the intestine is reached

some of it would be left as insoluble phosphate. A few grams of

bicarbonate daily would have equal therapeutic value with this water.

The advice based on the indications of methyl red and the urine is bad.

The committee’s report was sent to the Kalak Water Company for comment.

The company promised to withdraw the advertising circular referred to

in the report and disclaimed responsibility for the accuracy and value

of the set of indicators which it sent out, but, on the whole, the

previous advertising claims were insisted on.

In view of the absurd and false claims made for the product the Council

declared Kalak Water inadmissible to N. N. R.--(_From Reports of

Council on Pharmacy and Chemistry, 1917, p. 148._)

MINSON’S SOLUBLE IODIN “KELPIDINE” NOT ADMITTED TO N. N. R.

Report of the Council on Pharmacy and Chemistry

Minson’s Soluble Iodin “Kelpidine” was submitted to the Council by

J. J. Minson, Washington, D. C., trading as the Kelpidine Company,

with the statement that in future “literature” it was to be known as

Minson’s Soluble Iodin, only. The following statement of composition

was furnished:

“Minson’s Soluble Iodin is somewhat of an indefinite character,

chemically. Its formula is, Iodin 4 per cent., Distilled Water

6 per cent., and Absolute Alcohol _q. s._ 100 per cent. By a

process of chilling and heating an iodid of uncertain character is

produced, and because of the extreme sensitiveness of the product

to chemical tests, it is hard to determine. So far as I have been

able to judge, however, the result is about 3 or 3-1/2 per cent.

free iodin and from 1/2 per cent. to 1 per cent. iodid, possibly

ethyl and hydrogen iodid in combination.”

The A. M. A. Chemical Laboratory reports that the preparation is an

alcoholic solution containing free iodin and iodid, probably hydrogen

iodid and ethyl iodid, but that the free iodin content was only

2.69 gm. per 100 c.c.

It is claimed that the “therapeutic indications” of Minson’s Soluble

Iodin are the “same as those of all iodin and iodid preparations,

internally, externally, hypodermically and intravenously; excepting,

however, counter irritation.” It is admitted that there are no

“clinical reports” as to the hypodermic and intravenous use, but the

belief is expressed “that in an emergency it is a safe remedy under

proper dilution.” It is further claimed that “for all practical

purposes it is nontoxic and nonirritating” and that “it has none of

the undesirable features such as is the case with the iodids and the

organic preparations of iodin, proprietary or otherwise.”

It was assigned for consideration to the Committee on Pharmacology,

whose referee reported:

“According to the information submitted, this is a tincture of iodin;

differing from the official tincture in that it is more dilute and in

that hydrogen and ethyl iodid is the solvent in place of potassium

iodid. It is practically immaterial for internal administration,

whether the cation of the solvent iodid is hydrogen, ethyl, potassium

or sodium. It would certainly be inadvisable to inject a preparation

containing free iodin hypodermically. It is not ‘a safe remedy’ for

intravenous injection and it would not be nonirritant. The statement

that ‘it has none of the undesirable features’ of other iodin compounds

is inherently impossible. Apparent freedom of any iodin preparation

from undesirable effects is generally due to the use of small doses.

Such claims are plainly therapeutic exaggerations and therefore in

conflict with Rule 6. Even should these be removed, the preparation

must be held an unessential modification of the official tincture, and

therefore in conflict with Rule 10.”

The report was agreed to by the committee and adopted by the Council

and Minson’s Soluble Iodin “Kelpidine” declared inadmissible to New

and Nonofficial Remedies.--(_From Reports of Council on Pharmacy and

Chemistry, 1917, p. 152._)

NUTONE

Report of the Council on Pharmacy and Chemistry

NuTone (NuTone Company, Lowell, Mass.) is a “nutritive tonic” said to

have the following complex composition:

Cod Liver Oil, Pure Norwegian, 25 per cent.

Malt Extract, 9-1/3 per cent.

Beef juice,

Glycerine,

Hypophosphite Lime, Hypophosphite Soda, Chemically pure,

1-1/2 grs. each to the oz.

Fl. Ext. Nux Vomica, 3/64 of a minimum in each teaspoonful.

It is advertised with claims that will lead thoughtless physicians

and a confiding public to depend on it in cases in which fresh air,

hygienic surroundings and nutritious food are of prime importance.

The Propaganda for Reform in Proprietary Medicines, Vol. 2 of 2 · 第 5 / 20 章